Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Tarceva erlotinib: Phase I

In a dose-escalating U.S. Phase I trial, 8 of 49 (16%) patients given

Read the full 139 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE